Syndax Pharmaceuticals (SNDX) News Today $19.10 -0.50 (-2.55%) (As of 09/6/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period September 6 at 4:05 PM | prnewswire.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)September 5 at 9:30 AM | msn.comSyndax Pharmaceuticals, Inc. (SNDX): This Small-Cap Healthcare Stock Is A Good Buy Right NowSeptember 4 at 4:27 PM | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 3.4% Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 3.4%September 1, 2024 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Panagora Asset Management Inc.Panagora Asset Management Inc. cut its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 65.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 82,849 shares of the company's stock after selling 154,157 shares during the periAugust 28, 2024 | americanbankingnews.comBrokerages Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Target Price at $35.33August 25, 2024 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by AnalystsSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) has been given an average rating of "Moderate Buy" by the ten brokerages that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and nine have issued a buy ratingAugust 20, 2024 | marketbeat.comSG Americas Securities LLC Makes New $637,000 Investment in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)SG Americas Securities LLC acquired a new stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 31,051 shares of theAugust 18, 2024 | marketbeat.comAssenagon Asset Management S.A. Has $8.81 Million Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Assenagon Asset Management S.A. lifted its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 54.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 428,949 sharesAugust 16, 2024 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) PT Raised to $34.00Citigroup upped their price objective on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the company a "buy" rating in a research note on Friday.August 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Syndax Pharmaceuticals Amid Niktimvo’s Promising Market Entry and EfficacyAugust 15, 2024 | finance.yahoo.comFDA greenlights Incyte and Syndax’s GvHD drug NiktimvoAugust 15, 2024 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Given New $31.00 Price Target at Bank of AmericaBank of America boosted their target price on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a "buy" rating in a research note on Thursday.August 15, 2024 | finance.yahoo.comFDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant ComplicationAugust 12, 2024 | prnewswire.comSyndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute LeukemiaAugust 5, 2024 | prnewswire.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)August 4, 2024 | marketbeat.comVanguard Group Inc. Purchases 591,631 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Vanguard Group Inc. raised its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 13.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,926,984 shares of the company's stock after buyAugust 3, 2024 | msn.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q2 2024 Earnings Call TranscriptAugust 3, 2024 | finance.yahoo.comDespite currently being unprofitable, Syndax Pharmaceuticals (NASDAQ:SNDX) has delivered a 113% return to shareholders over 5 yearsAugust 2, 2024 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Releases Earnings Results, Beats Expectations By $0.11 EPSSyndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.91) by $0.11. The company had revenue of $3.50 million for the quarter. During the same period in the previous year, the business posted ($0.64) EPS. The firm's revenue was up 3499999990.0% on a year-over-year basis.August 2, 2024 | markets.businessinsider.comBuy Rating Affirmed on Syndax Pharmaceuticals Amid Strong Trial Results and Solid Financial PositionAugust 2, 2024 | markets.businessinsider.comStrong Buy Rating for Syndax Pharmaceuticals Amid Positive Drug Approval ProspectsAugust 1, 2024 | msn.comSyndax's revumenib granted FDA orphan drug designation for leukemiaAugust 1, 2024 | prnewswire.comSyndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business UpdateAugust 1, 2024 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) to Post FY2024 Earnings of ($4.07) Per Share, HC Wainwright ForecastsSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - Analysts at HC Wainwright decreased their FY2024 earnings per share estimates for shares of Syndax Pharmaceuticals in a research report issued on Monday, July 29th. HC Wainwright analyst E. White now anticipates that the company will postJuly 31, 2024 | markets.businessinsider.comMaintained Buy Rating on Syndax Pharmaceuticals Amid Revumenib Approval DelayJuly 31, 2024 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) has been given an average rating of "Moderate Buy" by the nine analysts that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company.July 30, 2024 | investorplace.com3 Biotech Stocks That Could Make Your Summer UnforgettableJuly 30, 2024 | finanznachrichten.deSyndax Pharmaceuticals, Inc.: Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute LeukemiaJuly 30, 2024 | msn.comSyndax drops as FDA extends target date for leukemia drug applicationJuly 30, 2024 | markets.businessinsider.comBuy Rating Affirmed for Syndax Pharmaceuticals Amidst Promising Revumenib Prospects and Robust Financial OutlookJuly 30, 2024 | markets.businessinsider.comOptimistic Buy Rating Maintained for Syndax Pharmaceuticals Amidst PDUFA Delay and Upcoming CatalystsJuly 29, 2024 | investopedia.comFDA Delays Decision on Syndax Leukemia Drug; Stock SinksJuly 29, 2024 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Given Buy Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $41.00 price target on shares of Syndax Pharmaceuticals in a research note on Monday.July 29, 2024 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down to $24.49Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down to $24.49July 29, 2024 | prnewswire.comSyndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute LeukemiaJuly 26, 2024 | marketbeat.comSyndax Pharmaceuticals (SNDX) Scheduled to Post Earnings on ThursdaySyndax Pharmaceuticals (NASDAQ:SNDX) will be releasing earnings after the market closes on Thursday, August 1, Zacks reports.July 25, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Syndax Pharmaceuticals (SNDX)July 25, 2024 | prnewswire.comSyndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024July 19, 2024 | marketbeat.comBNP Paribas Financial Markets Sells 117,303 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)BNP Paribas Financial Markets lowered its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 72.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 45,602 shares of the company's stock after selJuly 15, 2024 | marketbeat.comSusquehanna Fundamental Investments LLC Takes $2.61 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Susquehanna Fundamental Investments LLC acquired a new stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 109,827 shares of theJuly 14, 2024 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Short Interest UpdateSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) was the recipient of a large drop in short interest during the month of June. As of June 30th, there was short interest totalling 8,340,000 shares, a drop of 15.9% from the June 15th total of 9,920,000 shares. Based on an average trading volume of 1,030,000 shares, the short-interest ratio is presently 8.1 days.July 13, 2024 | marketbeat.comNvwm LLC Purchases New Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Nvwm LLC acquired a new stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 42,962 shares of the company's stock, valued at approxiJuly 8, 2024 | marketbeat.comVanguard Group Inc. Boosts Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Vanguard Group Inc. boosted its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 19.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,335,353 shares of theJuly 7, 2024 | marketbeat.comPrincipal Financial Group Inc. Has $448,000 Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Principal Financial Group Inc. cut its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 65.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 18,829 shares of the company's stock after sellingJuly 5, 2024 | prnewswire.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)June 28, 2024 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Research Coverage Started at Jefferies Financial GroupJefferies Financial Group initiated coverage on Syndax Pharmaceuticals in a research report on Friday. They issued a "buy" rating and a $37.00 price objective for the company.June 26, 2024 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $42.00 at Stifel NicolausStifel Nicolaus increased their target price on shares of Syndax Pharmaceuticals from $40.00 to $42.00 and gave the stock a "buy" rating in a report on Wednesday.June 21, 2024 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Trading Up 3.1%Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Up 3.1%June 21, 2024 | seekingalpha.comSyndax: Gearing Up For LaunchesJune 20, 2024 | marketbeat.comWellington Management Group LLP Reduces Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Wellington Management Group LLP cut its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 0.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 7,585,221 shares of the company's stock a Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Email Address War on Elon Escalates… (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth. One company holds a near-total monopoly on it. SNDX Media Mentions By Week SNDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNDX News Sentiment▼0.900.55▲Average Medical News Sentiment SNDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNDX Articles This Week▼44▲SNDX Articles Average Week Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AMPH News ENTA News VKTX News OGN News CYTK News BPMC News KRYS News NUVL News APLS News RARE News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNDX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.